Karyopharm to Present at the 15th Annual BIO Investor Forum
October 11 2016 - 7:30AM
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage
pharmaceutical company, today announced that Justin A. Renz,
Executive Vice President, Chief Financial Officer, and Treasurer,
will present at the 15th Annual BIO Investor Forum on Tuesday,
October 18, 2016 at 11:00 a.m. PT. The conference will be held at
the Westin St. Francis in San Francisco.
A live webcast of the event can be accessed
under "Events & Presentations" in the Investors section of the
Company's website at http://investors.karyopharm.com/events.cfm. A
replay of the webcast will be archived on the Company's website for
30 days following the presentation.
About Karyopharm
Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a
clinical-stage pharmaceutical company focused on the discovery and
development of novel first-in-class drugs directed against nuclear
transport and related targets for the treatment of cancer and other
major diseases. Karyopharm's SINE™ compounds function by binding
with and inhibiting the nuclear export protein XPO1 (or CRM1). The
Company's initial focus is on seeking regulatory approval and
commercialization of its lead drug candidate, oral selinexor
(KPT-330). To date, over 1,700 patients have been treated with
selinexor and it is currently being evaluated in several mid- and
later-phase clinical trials across multiple cancer indications,
including multiple myeloma in combination with low-dose
dexamethasone (STORM) and backbone therapies (STOMP), and in acute
myeloid leukemia (SOPRA), diffuse large B-cell lymphoma (SADAL),
and liposarcoma (SEAL), among others. Karyopharm plans to
initiate a pivotal randomized Phase 3 study of selinexor in
combination with bortezomib (Velcade®) and low-dose dexamethasone
(BOSTON) in patients with multiple myeloma in early 2017. In
addition to single-agent and combination activity against a variety
of human cancers, SINE™ compounds have also shown biological
activity in models of neurodegeneration, inflammation, autoimmune
disease, certain viruses and wound-healing. Karyopharm, which was
founded by Dr. Sharon Shacham, currently has five investigational
programs in clinical or preclinical development. For more
information, please visit www.karyopharm.com.
Contact:
Justin Renz
(617) 658-0574
jrenz@karyopharm.com
Gina Nugent
(617) 460-3579
nugentcomm@aol.com
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024